TrueBinding (United States)

This study aims to examine grammatical errors in opinion essays written by Post-Intermediate Level students at the Bali International Language Centre (BILCEN) at Triatma Mulya University, utilising DeepSeek AI to discover error trends and offer strategic advice for educators. A qualitative analysis of 17 articles revealed 109 grammatical problems, predominantly characterised by article omission errors (42.2%), followed by subject-verb agreement (26.6%), preposition errors (17.4%), and tense inconsistencies (13.8%). The primary reasons for these errors encompass first-language interference and sentence fragmentation, indicative of the impact of Indonesian structures on English production. Examples include “work in a cruise ship” rather than “work on a cruise ship.” This study underscores the significance of a teaching methodology incorporating contrastive exercises, targeted feedback, and task design that balances fluency and accuracy. Strategic recommendations involve implementing exercises that juxtapose Indonesian and English structures and utilizing DeepSeek AI’s functionalities to provide comprehensive feedback. This study presents a novel approach for educators to tackle systematic grammatical issues in EFL students’ opinion writing. It underscores the potential of AI to enhance the precision of academic writing.

Neurological disorders, such as Parkinson’s Disease and Alzheimer’s Disease, have become more common in recent years, with the number of deaths due to neurological disorders increasing by about 39% since 1990 (GBD 2016 Neurology collaborators, 2019). Neuroinflammation (NI), an inflammatory response within the brain or spinal cord has been shown to accelerate the development of Parkinson’s and Alzheimer’s disease. Conventional pharmaceutical drugs to treat NI can be expensive and promote financial burdens for chronic treatment. The goal of this study was to identify possible natural product alternatives that control NI and stable cell morphology. One viable alternative is curcumin, a chemical compound found in turmeric (Curcuma longa). Another alternative is fish oil, a natural product enriched with omega-3 fatty acids. Pretreatment with curcumin or fish oil significantly attenuated lipopolysaccharide (LPS)-induced cytokine release from acute and chronically treated BV-2 microglial cells and reduced Caspase 3/7 expression in HT-22 neuronal cells.

Abstract Characterized by rapid growth and diffusely infiltrative spread, glioblastoma (GBM) is the most common and most malignant primary brain cancer with a very poor prognosis and a standard of care that hasn’t been improved in over 15 years. The need for new therapies that can directly or indirectly target heterogeneous tumor cell populations to inhibit cell migration in addition to proliferation is highlighted by the recent efforts to develop targeted therapies to treat the vast majority of GBM patients whose tumors impede gross-total resection and develop resistance to chemoradiation. Galectin-3, a carbohydrate-binding protein overexpressed in astrocytes, microglia/macrophages, and the stroma of GBM tumors is a potent modulator of cell proliferation, migration, angiogenesis, T-cell inhibition, and M2 macrophage polarization. We and others have confirmed the association of Galectin-3 expression to lower survival in glioma patients. Additionally, tumor Galectin-3 levels have been shown to increase following exposure to temozolomide or radiation alone or in combination, thus more greatly increasing the need for targeting Galectin-3 in GBM patients following initial treatment. Here, we characterize the therapeutic effects of the anti-Galectin-3 antibody (Gal3 Ab) we have developed for the ability to inhibit GBM tumorigenic and metastatic potential in several in vitro assays and in vivo in heterotopic and orthotopic mouse models. Human GBM cells treated with Gal3 Ab show a significant decrease in cell viability, migration, and invasion in vitro. In vivo, the Gal3 Ab decreases tumor burden and provides a survival benefit in combination with temozolomide compared to the current standard-of-care treatment alone. Our studies indicate the potential for our novel anti-Galectin-3 to be added to the very limited arsenal of potential treatments for GBM. Citation Format: ANNE MARIE BARRETTE, Krutika Deshpande, Marvin Cadiente, Anji Bei, Xi Wang, Teodelinda Mirabella, Dongxu Sun. A novel anti-Galectin-3 antibody therapeutic for the treatment of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1146.